[Efficacy of levofloxacin 500 mg for middle ear diseases].

Takashi Kimitsuki, Takamasa Yoshida, Shizuo Komune

研究成果: ジャーナルへの寄稿記事

抄録

We examined the cases that prescribed levofloxacin (LVFX) 500mg for middle ear diseases in our hospital. LVFX 500mg was prescribed in 18 cases (7 male, 11 female, 24-81 years old). LVFX was mainly used for the following clinical conditions, 1) otitis media with granulation proliferation: 3 cases, 2) infection to an artificial materials : 5 cases, 3) treatment for or prevention against the inflammation of the inner ear: 4 cases. Three of eighteen cases were ineffective by LVFX treatment. Bacteriological examination indicated LVFX-resistant MRSA or Pseudomonas aeruginosa were isolated in these three cases.

元の言語英語
ページ(範囲)43-48
ページ数6
ジャーナルFukuoka igaku zasshi = Hukuoka acta medica
103
発行部数2
出版物ステータス出版済み - 2 2012

Fingerprint

Ear Diseases
Levofloxacin
Middle Ear
Otitis Media
Inner Ear
Methicillin-Resistant Staphylococcus aureus
Pseudomonas aeruginosa
Inflammation
Infection

All Science Journal Classification (ASJC) codes

  • Medicine(all)

これを引用

Kimitsuki, T., Yoshida, T., & Komune, S. (2012). [Efficacy of levofloxacin 500 mg for middle ear diseases]. Fukuoka igaku zasshi = Hukuoka acta medica, 103(2), 43-48.

[Efficacy of levofloxacin 500 mg for middle ear diseases]. / Kimitsuki, Takashi; Yoshida, Takamasa; Komune, Shizuo.

:: Fukuoka igaku zasshi = Hukuoka acta medica, 巻 103, 番号 2, 02.2012, p. 43-48.

研究成果: ジャーナルへの寄稿記事

Kimitsuki, T, Yoshida, T & Komune, S 2012, '[Efficacy of levofloxacin 500 mg for middle ear diseases].', Fukuoka igaku zasshi = Hukuoka acta medica, 巻. 103, 番号 2, pp. 43-48.
Kimitsuki, Takashi ; Yoshida, Takamasa ; Komune, Shizuo. / [Efficacy of levofloxacin 500 mg for middle ear diseases]. :: Fukuoka igaku zasshi = Hukuoka acta medica. 2012 ; 巻 103, 番号 2. pp. 43-48.
@article{7b79cf14ab28498388b5c19b647e13c3,
title = "[Efficacy of levofloxacin 500 mg for middle ear diseases].",
abstract = "We examined the cases that prescribed levofloxacin (LVFX) 500mg for middle ear diseases in our hospital. LVFX 500mg was prescribed in 18 cases (7 male, 11 female, 24-81 years old). LVFX was mainly used for the following clinical conditions, 1) otitis media with granulation proliferation: 3 cases, 2) infection to an artificial materials : 5 cases, 3) treatment for or prevention against the inflammation of the inner ear: 4 cases. Three of eighteen cases were ineffective by LVFX treatment. Bacteriological examination indicated LVFX-resistant MRSA or Pseudomonas aeruginosa were isolated in these three cases.",
author = "Takashi Kimitsuki and Takamasa Yoshida and Shizuo Komune",
year = "2012",
month = "2",
language = "English",
volume = "103",
pages = "43--48",
journal = "Fukuoka Acta Medica",
issn = "0016-254X",
publisher = "福岡医学会",
number = "2",

}

TY - JOUR

T1 - [Efficacy of levofloxacin 500 mg for middle ear diseases].

AU - Kimitsuki, Takashi

AU - Yoshida, Takamasa

AU - Komune, Shizuo

PY - 2012/2

Y1 - 2012/2

N2 - We examined the cases that prescribed levofloxacin (LVFX) 500mg for middle ear diseases in our hospital. LVFX 500mg was prescribed in 18 cases (7 male, 11 female, 24-81 years old). LVFX was mainly used for the following clinical conditions, 1) otitis media with granulation proliferation: 3 cases, 2) infection to an artificial materials : 5 cases, 3) treatment for or prevention against the inflammation of the inner ear: 4 cases. Three of eighteen cases were ineffective by LVFX treatment. Bacteriological examination indicated LVFX-resistant MRSA or Pseudomonas aeruginosa were isolated in these three cases.

AB - We examined the cases that prescribed levofloxacin (LVFX) 500mg for middle ear diseases in our hospital. LVFX 500mg was prescribed in 18 cases (7 male, 11 female, 24-81 years old). LVFX was mainly used for the following clinical conditions, 1) otitis media with granulation proliferation: 3 cases, 2) infection to an artificial materials : 5 cases, 3) treatment for or prevention against the inflammation of the inner ear: 4 cases. Three of eighteen cases were ineffective by LVFX treatment. Bacteriological examination indicated LVFX-resistant MRSA or Pseudomonas aeruginosa were isolated in these three cases.

UR - http://www.scopus.com/inward/record.url?scp=84861815468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861815468&partnerID=8YFLogxK

M3 - Article

C2 - 22568127

AN - SCOPUS:84861815468

VL - 103

SP - 43

EP - 48

JO - Fukuoka Acta Medica

JF - Fukuoka Acta Medica

SN - 0016-254X

IS - 2

ER -